Financial Symmetry’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Financial Symmetry’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$707	Hold	10,191	–	–	﹤0.01%	68
2026 Q1	$581	Hold	10,191	–	–	﹤0.01%	63
2025 Q4	$570	Hold	10,191	–	–	﹤0.01%	60
2025 Q3	$907	Hold	10,191	–	–	﹤0.01%	53
2025 Q2	$763	Hold	10,191	–	–	﹤0.01%	48
2025 Q1	$1.02K	Hold	10,191	–	–	﹤0.01%	50
2024 Q4	$1.22K	Hold	10,191	–	–	﹤0.01%	44
2024 Q3	$998	Hold	10,191	–	–	﹤0.01%	46
2024 Q2	$1.28K	Hold	10,191	–	–	﹤0.01%	41
2024 Q1	$1.86K	Hold	10,191	–	–	﹤0.01%	36
2023 Q4	$978	Buy	+10,191	New	+$978	﹤0.01%	32

Other funds holding PVCT

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Atlas Wealth Cincinnati, Ohio $701M AUM 15.28% 1-Year Est. Return

Financial Symmetry's PVCT Position: Q2 2026 in Review

Financial Symmetry held its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) position steady in Q2 2026 at 10,191 shares worth $707. The position accounts for ﹤0.01% of the portfolio, ranked #68.

Financial Symmetry first reported a position in PVCT in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.86K in Q1 2024. 3 funds tracked by Wall St. Rank hold PVCT as of Q2 2026.

Financial Symmetry held 10,191 shares of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) worth $707 as of Q2 2026.
Financial Symmetry left its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) share count unchanged in Q2 2026.
PROVECTUS BIOPHARMACEUTICALS, INC. (DE) made up ﹤0.01% of Financial Symmetry's portfolio in Q2 2026, its #68 holding.
Financial Symmetry first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2023 and has held it in 11 quarters since.
Financial Symmetry's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $1.86K in Q1 2024.
3 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q2 2026.

Based on Financial Symmetry's 13F filing for Q2 2026, filed 14 Jul 2026.